Patents Examined by Daniel C Gamett
  • Patent number: 10597731
    Abstract: A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 24, 2020
    Assignees: UbiVac, LLC, Providence Health & Services-Oregon
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Patent number: 10597732
    Abstract: A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: March 24, 2020
    Assignees: UbiVac, LLC, Providence Health & Services-Oregon
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Patent number: 10589132
    Abstract: An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: March 17, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Eldad Tzahor, Elad Bassat
  • Patent number: 10591465
    Abstract: Disclosed is a method for labeling, detecting and/or isolating Foxp3+ Treg cells from a biological sample containing peripheral blood mononuclear cells (PBMC) or lymphocytes including the following steps of: (i) coupling the surface of PBMC or lymphocytes to a capture moiety which binds to the cell through a cell surface molecule and to interleukin-34 (IL34), (ii) culturing the lymphocytes under conditions wherein IL34 is secreted, released and specifically captured by the capture moiety, (iii) labeling the IL34 expressing lymphocytes with a label moiety, and (iv) optionally detecting and/or isolating the IL34 expressing lymphocytes which are Foxp3+ Treg cells. Also disclosed is an isolated population of Foxp3+ Treg cells obtainable by the method and uses thereof.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: March 17, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE NANTES, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Carole Guillonneau, Ignacio Anegon, Severine Bezie
  • Patent number: 10590385
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: March 17, 2020
    Assignee: NKMAX CO., LTD.
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • Patent number: 10590387
    Abstract: Provided herein are isolated CD133+ cells, such as human CD133+ cells, that have been expanded in culture and populations of isolated CD133+ cells that have been expanded in culture. The cells express transcription factors, growth factors, or a combination thereof, at altered levels compared to a naturally occurring CD133+ cell. Also provided are methods, including methods for expanding CD133+ cells and methods for using CD133+ cells.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: March 17, 2020
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Larry Denner, Randall J. Urban, Yvonne Bodenburg
  • Patent number: 10584180
    Abstract: A composition for treating inflammation or auto-immune disorders comprises (i) an antibody that binds to an AGE-modified protein on a cell, and (ii) an anti-inflammation antibody. Furthermore, the antibody that binds to an AGE-modified protein on a cell is also effective to treat inflammation or auto-immune disorders alone.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: March 10, 2020
    Assignee: Siwa Corporation
    Inventor: Lewis S. Gruber
  • Patent number: 10577586
    Abstract: The invention provides methods of modulating follicular regulatory T (TFR) cell-mediated immune responses, follicular helper T (TFH) cell-mediated immune responses or both, and the use of those methods in the treatment of diseases or conditions mediated by TFR or TFH cells. The invention also provides novel methods for identifying TFR and TFH cells in a population of cells. The invention also provides compositions comprising TFR cells that have enhanced suppressive activity as compared wild type TFR cells. The invention also provides compositions comprising T follicular regulatory (TFR) cells isolated from the peripheral blood of a subject wherein the composition is enriched for TFR cells. Methods of making and using the compositions of the invention to modulate an immune response are also provided.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: March 3, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Arlene H. Sharpe, Peter T. Sage, Loise M. Francisco
  • Patent number: 10568989
    Abstract: The present invention concerns the enhancement of the osteogenic potential of bone graft by ex vivo treatment with a Wnt polypeptide, such as a liposomal Wnt polypeptide.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: February 25, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jill Helms, Girija Dhamdhere
  • Patent number: 10561740
    Abstract: The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 18, 2020
    Inventors: Kevin P. Dooley, Rane A. Harrison, Russell E. McConnell, Ke Xu, Damian J. Houde, Nikki Ross, Sonya Haupt, John D. Kulman, Douglas E. Williams
  • Patent number: 10563171
    Abstract: The invention provides a method for inducing human primordial germ cell-like (PGC-like) cells from human pluripotent stem cells, with high efficiency and high reproducibility, and a cell surface marker for identifying human PGC-like cells. In particular, the invention provides a method for producing a human PGC-like cell from a human pluripotent stem cell, includes a step of producing a mesoderm-like cell by culturing a human pluripotent stem cell in a culture medium comprising activin A and a GSK3? inhibitor, and a step of culturing the mesoderm-like cell in a culture medium containing BMP. The invention also provides a method for producing an isolated human PGC-like cell, which includes the aforementioned two steps and the additional step of selecting a cell positive to at least one cell surface marker selected from the group consisting of PECAM (CD31), INTEGRIN?6 (CD49f), INTEGRIN?3 (CD61), KIT (CD117), EpCAM, PODOPLANIN and TRA1-81.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: February 18, 2020
    Assignee: Kyoto University
    Inventors: Mitinori Saitou, Kotaro Sasaki, Shihori Yokobayashi
  • Patent number: 10550369
    Abstract: The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: February 4, 2020
    Assignee: Mesoblast International Sarl
    Inventors: Samson Tom, Christopher Ton, Alla Danilkovitch
  • Patent number: 10550166
    Abstract: The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: February 4, 2020
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Bernard Maillere, Claire Chevaleyre, Florence Castelli-Golfier, Emmanuel Favry, Anaïs M'Houmadi
  • Patent number: 10548976
    Abstract: Provided herein are methods of treating beta-thalassemia in a subject comprising administering to the subject an activin type II receptor (ActRII) signaling inhibitor (e.g., an activin ligand trap) and utilizing one or more in vitro cell culture methods provided herein in (i) selection of the subject to be treated according to the methods provided herein; and/or (ii) monitoring of the subject being treated according to the methods provided herein.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: February 4, 2020
    Assignee: Celgene Corporation
    Inventors: Maria Cappellini, Victoria Sung
  • Patent number: 10532088
    Abstract: The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR?) and provides adoptive cellular therapies using an agonist of ROR?, populations of lymphocyte cells that have been exposed to an agonist of ROR?, populations of dendritic cells that have been exposed to an agonist of ROR?, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR? to a patient.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: January 14, 2020
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Xiao Hu, Thomas D. Aicher, Laura Lee Celeste, Xikui Liu, Clarke B. Taylor, Chad A. Van Huis
  • Patent number: 10527631
    Abstract: Methods and compositions are provided for the selective activation of a BMP-dependent response in certain cell types. Methods include identifying a ligand or ligand combinations as well as cell receptor profiles that result in selectively activating a ligand-dependent response through interactions with ligand receptors on a first cell type that do not activate the ligand-dependent response in a second cell type.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 7, 2020
    Assignee: California Institute of Technology
    Inventors: Yaron E. Antebi, James Linton, Michael Elowitz, Heidi Klumpe
  • Patent number: 10525110
    Abstract: The technology relates in part to methods for inducing partial apoptosis of cells that express an inducible caspase polypeptide. The technology further relates in part to methods for inducing partial apoptosis of cells that express an inducible modified caspase polypeptide, having a modified dose response curve to the multimeric ligand inducer. The technology also relates in part to methods for cell therapy using cells that express the inducible caspase polypeptide or the inducible modified caspase polypeptide, where the proportion of caspase polypeptide-expressing cells eliminated by apoptosis is related to the administered amount of the multimeric ligand inducer.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: January 7, 2020
    Assignee: Bellicum Pharmaceuticals, Inc.
    Inventors: Kevin Slawin, David Spencer, Aaron Edward Foster
  • Patent number: 10519423
    Abstract: Pro-fibrotic signaling potently antagonizes cardiac reprogramming. Inhibition of pro-fibrotic signaling using small molecules that target the transforming growth factor-?/SMAD, or Rho kinase leads to conversion of approximately 60% of fibroblasts into beating cardiomyocytes. Conversely, over-activation of these pro-fibrotic signaling networks inhibits cardiac reprogramming. Using the disclosed methods, fibroblasts are converted to spontaneously contracting cardiomyocytes in less than two weeks.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: December 31, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Kunhua Song, Yuanbiao Zhao, Pilar Londono, Timothy McKinsey
  • Patent number: 10517931
    Abstract: Described herewith are compositions comprising placental growth factors and methods for non-surgical, localized delivery thereof. The composition is delivered to a diseased or injured organ and/or body part and is formulated in a manner which allows for localized retention of the composition at the site of delivery.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: December 31, 2019
    Assignee: MiMedx Group, Inc.
    Inventors: Thomas J. Koob, Rebeccah J. C. Brown
  • Patent number: 10520494
    Abstract: The present invention relates to the use of the biomarker Flattop (Fltp) for distinguishing mature ? cells from immature progenitor ? cells. The present invention further relates to a method for distinguishing a mature ? cell from an immature progenitor ? cell, the method comprising: determining the presence or absence of the biomarker Flattop (Fltp) in a ? cell; wherein the presence of Fltp in the cell indicates that the cell is a mature ? cell and wherein the absence of Fltp in the cell indicates that the cell is an immature progenitor ? cell. Furthermore, the present invention relates to a method of identifying a compound suitable for differentiating immature progenitor ? cells into mature ? cells as well as to a method of identifying a compound suitable for preventing the de-differentiating of mature ? cells.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: December 31, 2019
    Assignee: Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (GmbH)
    Inventors: Heiko Lickert, Adriana Migliorini, Moritz Gegg, Erik Bader